Suven Life Sciences secures Product Patents in Australia and Singapore
"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that is being developed for cognitive disorders with high unmet medical need with huge market potential globally," says Venkat Jasti, CEO of Suven Life Sciences.
Hyderabad: Suven Life Sciences Ltd recently announced that the grant of one product patent from Australia and one product patent from Singapore corresponding to the New Chemical Entities for the treatment of disorders associated with Neurodegenerative diseases and patents are valid through 2036.
The granted claims of the patents include the class of selective 5-HT4 and M1 PAM compounds respectively and are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia etc.
"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that is being developed for cognitive disorders with high unmet medical need with huge market potential globally," says Venkat Jasti, CEO of Suven.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products. Suven has 4 clinical stage compounds, a Phase 2 undergoing SUVN502, Phase 2 ready SUVN-G3031, Phase 1 completed SUVN-D4010 and SUVN-911.
In addition to these clinical compounds, the Company has nine (9) internally-discovered therapeutic drug candidates currently in various stages of pre-clinical development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and pain.
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at firstname.lastname@example.org Contact no. 011-43720751 To know about our editorial team click here